Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer

PURPOSE: PF-05280014 is a biosimilar to trastuzumab (Herceptin(®)). Following demonstration of pharmacokinetic (PK) similarity in healthy volunteers, a comparative clinical study in patients with HER2-positive metastatic breast cancer (mBC) compared the efficacy, safety and immunogenicity of PF-0528...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaoying, Li, Cheryl, Ewesuedo, Reginald, Yin, Donghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586910/
https://www.ncbi.nlm.nih.gov/pubmed/31053945
http://dx.doi.org/10.1007/s00280-019-03850-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586910/
https://www.ncbi.nlm.nih.gov/pubmed/31053945
http://dx.doi.org/10.1007/s00280-019-03850-1

Ejemplares similares